Intraperitoneal il-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/lactate-based peritoneal dialysis solutions

Peritoneal Dialysis International

Volumn 32, Issue 1, 2012, Pages 37-44

  Opatrna, Sylvie ^a   Lysak, Daniel ^a   Trefil, Ladislav ^a   Parker, Clare ^b   Topley, Nicholas ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Biocompatibility; Glycoprotein 130; Icodextrin; Interleukin 6; Interleukin 6 receptor; Peritoneal dialysis solution

Indexed keywords

C REACTIVE PROTEIN; CREATININE; GLUCOSE BICARBONATE; GLYCOPROTEIN GP 130; ICODEXTRIN; INORGANIC SALT; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LACTIC ACID; PERITONEAL DIALYSIS FLUID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOCOMPATIBILITY; CELL ISOLATION; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIALYSATE; EFFLUENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; INFLAMMATION; KIDNEY FAILURE; LEUKOCYTE DIFFERENTIAL COUNT; MALE; MESOTHELIUM CELL; NORMAL VALUE; PERITONITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ULTRAFILTRATION;

ADULT; AGED; BICARBONATES; DIALYSIS SOLUTIONS; DRUG COMBINATIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GLUCANS; GLUCOSE; HUMANS; INTERLEUKIN-6; LACTIC ACID; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONEUM; PROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; TIME FACTORS; YOUNG ADULT;

EID: 84856672705     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2010.00235     Document Type: Article

References (32)

1. Mistry CD, Mallick NP, Gokal R. Ultrafiltration with isosmotic solution during long peritoneal dialysis exchanges. Lancet 1987; 2:178-82.
2. Mistry CD, Gokal R, Peers E. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 1994; 46:496-503.
3. Wolfson M, Piraino B, Hamburger RJ, Morton AR on behalf of the Icodextrin Study Group. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 2002; 40:1055-65.
4. Kim YL. Update on mechanisms of ultrafiltration failure. Perit Dial Int 2009; 29(Suppl 2):S123-7.
5. Lameire N. Volume control in peritoneal dialysis patients: role of new dialysis solutions. Blood Purif 2004; 22:44-54.
6. Davies SJ, Brown EA, Frandsen NE, Rodrigues AS, Rodriguez-Carmona A, Vychytil A, et al. Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 2005; 67:1609-15.
7. Opatrná S, Opatrný K Jr, Racek J, Sefrna F. Effect of icodextrin-based dialysis solution on peritoneal leptin clearance. Perit Dial Int 2003; 23:89-91.
8. Guo A, Wolfson M, Holt R. Early quality of life benefits of icodextrin in peritoneal dialysis. Kidney Int Suppl 2002; 81:S72-9.
9. Kuriyama R, Tranæus A, Ikegami T. Icodextrin reduces mortality and the drop-out rate in Japanese peritoneal dialysis patients. Adv Perit Dial 2006; 22:108-10.
10. Han SH, Ahn SV, Yun JY, Tranæus A, Han DS. Mortality and technique failure in peritoneal dialysis patients using advanced peritoneal dialysis solution. Am J Kidney Dis 2009; 54:711-20.
11. Cooker LA, Holmes CJ, Hoff CM. Biocompatibility of icodextrin. Kidney Int Suppl 2002; 81:S34-45.
12. Schalkwijk CG, Wee PM, Teerlink T. Reduced 1,2-dicarbonyl compounds in bicarbonate/lactate-buffered peritoneal dialysis fluids based on glucose polymers or amino acids. Perit Dial Int 2000; 20:796-8.
13. Parikova A, Zweers MM, Struijk DG, Krediet RT. Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions. Adv Perit Dial 2003; 19:186-90.
14. Martikainen TA, Teppo AM, Grönhagen-Riska C, Ekstrand AV. Glucose-free dialysis solutions: inductors of an inflammation or preservers of peritoneal membrane? Perit Dial Int 2005; 25:453-60.
15. Moriishi M, Kawanishi H. Icodextrin and intraperitoneal inflammation. Perit Dial Int 2008; 28(Suppl 3):S96-100.
16. Lai KN, Lai KB, Lam CW, Chan TM, Li FK, Leung JC. Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2000; 35:644-52.
17. Roberts GW, Baird D, Gallagher K, Jones RE, Pepper CJ, Williams JD, et al. Functional effector memory T cells enrich the peritoneal cavity of patients treated with peritoneal dialysis. J Am Soc Nephrol 2009; 20:1895-1900.
18. Pecoits-Filho R, Carvalho MJ, Stenvinkel P, Lindholm B, Heimbürger O. Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int 2006; 26:53-63.
19. Devuyst O, Topley N. Peritoneal membrane transport: driving under the influence. Perit Dial Int 2006; 26:35-7.
20. Cooker LA, Luneburg P, Holmes CJ, Jones S, Topley N on behalf of the Bicarbonate/Lactate Study Group. Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions. Perit Dial Int 2001; 21(Suppl 3):S102-7.
21. Pajek J, Kveder R, Bren A, Gucek A, Ihan A, Osredkar J, et al. Short-term effects of a new bicarbonate/lactate-buffered and conventional peritoneal dialysis fluid on peritoneal and systemic inflammation in CAPD patients: a randomized controlled study. Perit Dial Int 2008; 28:44-52.
22. Weiss L, Stegmayr B, Malmsten G, Tejde M, Hadimeri H, Siegert CE, et al. Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int 2009; 29:647-55.
23. Do JY, Kim YL, Park JW, Chang KA, Lee SH, Ryu DH, et al. The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis. Perit Dial Int 2008; 28(Suppl 3):S101-6.
24. Nascimento MM, Suliman ME, Silva M, Chinaglia T, Marchioro J, Hayashi SY, et al. Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study. Perit Dial Int 2010; 30:336-42.
25. Bender TO, Witowski J, Ksiazek K, Jörres A. Comparison of icodextrin-and glucose-based peritoneal dialysis fluids in their acute and chronic effects on human peritoneal mesothelial cells. Int J Artif Organs 2007; 30:1075-82.
26. Plum J, Lordnejad MR, Grabensee B. Effect of alternative peritoneal dialysis solutions on cell viability, apoptosis/necrosis and cytokine expression in human monocytes. Kidney Int 1998; 54:224-35.
27. Parikova A, Zweers MM, Struijk DG, Krediet RT. Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions. Adv Perit Dial 2003; 19:186-90.
28. Lewis S, Holmes C. Host defense mechanisms in the peritoneal cavity of continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1991; 11:14-21.
29. Paniagua R, Ventura Mde J, Rodríguez E, Sil J, Galindo T, Hurtado ME, et al. Impact of fill volume on peritoneal clearances and cytokine appearance in peritoneal dialysis. Perit Dial Int 2004; 24:156-62.
30. Krediet RT, Ho-dac-Pannekeet MM, Imholz AL, Struijk DG. Icodextrin's effects on peritoneal transport. Perit Dial Int 1997; 17:35-41.
31. Hwang YH, Son MJ, Yang J, Kim K, Chung W, Joo KW, et al. Effects of interleukin-6 T15A single nucleotide polymorphism on baseline peritoneal solute transport rate in incident peritoneal dialysis patients. Perit Dial Int 2009; 29:81-8.
32. Pachaly MA, do Nascimento MM, Suliman ME, Hayashi SY, Riella MC, Manfro RC, et al. Interleukin-6 is a better predictor of mortality as compared to C-reactive protein, homocysteine, pentosidine and advanced oxidation. Blood Purif 2008; 26:204-10.